ACX-362E a Promising Potential Treatment for C difficile, First-in-Human Phase 1 Trial Demonstrates
October 2nd 2019Investigators observed no moderate, severe, cumulative, or dose-limiting adverse events leading to discontinuation, and ACX-362E was generally well-tolerated at all dose levels.
Read More
Does ABSSSI Treatment With Oritavancin More Effectively Prevent Bacteremia?
October 2nd 2019In a new study, a team of investigators set out to determine if oritavancin use can reduce the sequelae from ABSSSI treatment failures, while also preventing infection recurrences and improving patient outcomes.
Read More
Early Detection and Quick Infection Prevention Support Key to Tackling Candida Auris
October 2nd 2019When it came to infection prevention measures, 5 of the 9 Orange County facilities with C auris displayed hand hygiene adherence < 50%, 3 had limited access to alcohol-based hand rubs, and < 60% of assessed high-touch surfaces were clean.
Read More